Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting. - Wikidata - awgldk - TriplyDB

Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting.

Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting.

http://www.wikidata.org/entity/Q41162993

about

Adjunct Strategies for Tuberculosis Vaccines: Modulating Key Immune Cell Regulatory Mechanisms to Potentiate Vaccination Novel vaccination approaches to prevent tuberculosis in children A Higher Activation Threshold of Memory CD8+ T Cells Has a Fitness Cost That Is Modified by TCR Affinity during Tuberculosis Novel adjuvant formulations for delivery of anti-tuberculosis vaccine candidates Current status of new tuberculosis vaccine in children.A Randomized, Controlled Safety, and Immunogenicity Trial of the M72/AS01 Candidate Tuberculosis Vaccine in HIV-Positive Indian Adults.Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate.Emerging drugs and alternative possibilities in the treatment of tuberculosis.Towards new TB vaccines: What are the challenges?Bacillus Calmette-Guérin (BCG) Revaccination of Adults with Latent Mycobacterium tuberculosis Infection Induces Long-Lived BCG-Reactive NK Cell Responses.Innate signaling by mycobacterial cell wall components and relevance for development of adjuvants for subunit vaccines.Different Adjuvants Induce Common Innate Pathways That Are Associated with Enhanced Adaptive Responses against a Model Antigen in Humans.Vaccine adjuvants: Why and how.Adjuvant system AS01: helping to overcome the challenges of modern vaccines.Polyfunctional CD4+ T Cells As Targets for Tuberculosis Vaccination Multiantigenic subunitary vaccines against tuberculosis in clinical trials: Where do we stand and where do we need to go?The current status, challenges, and future developments of new tuberculosis vaccines.Adjuvant-Associated Peripheral Blood mRNA Profiles and Kinetics Induced by the Adjuvanted Recombinant Protein Candidate Tuberculosis Vaccine M72/AS01 in Bacillus Calmette-Guérin-Vaccinated Adults.Phase 2b Controlled Trial of M72/AS01 Vaccine to Prevent Tuberculosis The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial

P2860

Q28074536-2D2D8636-197E-4A73-BDFA-FF7AE0DD096F Q33801426-609EC052-B726-487E-9AFC-B4D2413D6D89 Q35888761-F4FE5AF7-C8EC-4EBE-BF62-4F72582DC881 Q36909492-F4427B3C-8271-4B64-9287-A9D7202C5BDA Q37130796-28C6147C-EF19-4CA2-9D59-F1542143B19D Q37204894-7BA49EF4-66EA-4183-A6D0-C39CA90BC738 Q37587612-9C550076-E6A0-4152-8EC9-FE0C9D25673A Q38724073-225E66DD-D752-43E4-8F1D-1BE2F2AEAA8F Q38767468-54DDEDFA-5EBB-4B95-B674-B6F9D9C1BB13 Q39604583-6A1E8170-74A0-45E4-A2EC-CD86B2D783CC Q39748955-CE94F935-3795-4FB6-B56C-9C7AC6E7238E Q40064119-AF2FFC88-ABD4-4A9F-8C36-8C1317DD4AEC Q40566411-79F88850-044B-4CA8-80E2-5EF35514BD6C Q42051427-19C501F9-4601-4A77-93B2-BD341B44FCD2 Q42373425-B73CB8F8-F327-4FCB-B5BA-529400BD169F Q42692800-FFCE42D1-3C0D-4FF2-9761-D0DEC5F8705D Q52337140-D62BFFCE-3B88-4FDF-9FC4-F512C8AF1D2F Q52597636-A60862B0-B19B-4A65-B527-0F0BED71D733 Q57069957-847F2881-D400-4B9C-930A-ECBD96307269 Q58765317-547B0730-86A8-45AD-9A94-288DAB1C7AAB

P2860

Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting.

http://www.wikidata.org/entity/Q41162993

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Safety and immunogenicity of c ...... cents in a TB endemic setting.

@en

type

label

Safety and immunogenicity of c ...... cents in a TB endemic setting.

@en

prefLabel

Safety and immunogenicity of c ...... cents in a TB endemic setting.

@en

P1433

Q41162993-34CBCE82-70F6-46D5-9398-5B099249E1DD

P1476

Q41162993-5FC2FB5E-DBF9-4D05-BC6F-F82BC0A0AF07

P2093

Q41162993-11042956-5A16-486D-8723-D001E0462922

Q41162993-1D63C2F0-595E-48CA-8F11-8D51E3EBCAF2

Q41162993-222F2000-EE4E-4FCB-9965-DE3CF2D7AA3A

Q41162993-3F94E578-013C-4C52-B167-0C34E96AD69B

Q41162993-671C9FBE-1942-4159-B6BA-B059385D5148

Q41162993-67790C6A-14D8-4DCE-A22E-E8BDA36A22C1

Q41162993-73EDD2EF-E6A6-484E-B8AB-51A14701893E

Q41162993-780B3FCD-939D-457D-97CE-42A595464DE2

Q41162993-803F112B-D113-4CF1-B632-B5514F3BFF35

Q41162993-9452D002-B526-43AD-8B9D-EB7E14799364

P2860

Q41162993-00505385-364E-4FCF-B080-3C3E61EFDC8A

Q41162993-0E28BF35-CCD2-4DCD-A7E8-39C67D331EFA

Q41162993-10D9DDB9-A7FD-40E9-A68F-424011E24D13

Q41162993-12430C24-95EC-4DDB-9070-EC6082C55BC9

Q41162993-22C6946B-03D6-4B19-86F1-D53FDEB953E7

Q41162993-29FA59A8-A3C8-4CAA-BA40-5199D72977EA

Q41162993-3186F030-583B-4B15-BC5A-C1BF7D52A276

Q41162993-3B22A5CF-55D7-4310-8065-7144C999E561

Q41162993-44D100FE-AC91-4456-93D7-3960B9B40AB5

Q41162993-4875AC99-48B8-4B79-A83E-8B26AD5634FC

P304

Q41162993-577F7693-A1A4-4033-B6F8-8FD3AD9C3E1D

P31

Q41162993-83175795-389D-412A-B2CB-E7FDC67A40C3

P356

Q41162993-9F2B0D9D-6B5C-45AE-9F2E-F2F2A300F9A1

P407

Q41162993-16DD3747-0552-42A7-894F-E5466A829278

P433

Q41162993-2EEA84AB-E0BC-4172-9E68-F24582D80D8F

P478

Q41162993-DA073783-1653-42BE-88D0-51AA58E4FB35

P50

Q41162993-01B18E2E-497A-4820-BDF1-E58F88BCF25F

Q41162993-AE43A875-B84B-4EDA-8F33-E113FAD25161

Q41162993-DB1F1345-4779-4D8C-B9D1-83B899905106

P577

Q41162993-AEE513E3-8951-4193-892A-9949CDF8B4CB

P5875

Q41162993-CF8E462E-0374-44FE-BDB0-4FADC054D99D

P698

Q41162993-640C471D-C143-4D5B-8F31-4B2789344D2E

P932

Q41162993-E29527E5-773C-4BCD-8DBC-643E62A970B2

P356

J.VACCINE.2015.05.088

P1433

P1476

Safety and immunogenicity of c ...... cents in a TB endemic setting.

@en

P2093

Adam Penn-Nicholson

http://www.w3.org/2001/XMLSchema#string

Angelique Kany Kany Luabeya

http://www.w3.org/2001/XMLSchema#string

Anne Bollaerts

http://www.w3.org/2001/XMLSchema#string

Cheryl L Day

http://www.w3.org/2001/XMLSchema#string

Didier Lapierre

http://www.w3.org/2001/XMLSchema#string

Erik Jongert

http://www.w3.org/2001/XMLSchema#string

Evi De Ruymaeker

http://www.w3.org/2001/XMLSchema#string

Hennie Geldenhuys

http://www.w3.org/2001/XMLSchema#string

Marie-Ange Demoitie

http://www.w3.org/2001/XMLSchema#string

Michele Tameris

http://www.w3.org/2001/XMLSchema#string

P2860

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

Prospects for Tuberculosis Elimination

Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial

Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice

A critical role for CD8 T cells in a nonhuman primate model of tuberculosis.

Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice

The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults.

CD4+ T-cell help enhances NK cell function following therapeutic HIV-1 vaccination.

Evaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F/AS02(A) candidate tuberculosis vaccine in purified protein derivative-negative adults.

P304

4025-4034

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2015.05.088

http://www.w3.org/2001/XMLSchema#string

P407

P433

32

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

Willem Albert Hanekom

Thomas J Scriba

P577

2015-06-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

278332145

http://www.w3.org/2001/XMLSchema#string

P698

26072017

http://www.w3.org/2001/XMLSchema#string

P932

5845829

http://www.w3.org/2001/XMLSchema#string